Dicerna Pharmaceuticals Price-to-Tangible-Book Historical Data
The historical data trend for Dicerna Pharmaceuticals's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dicerna Pharmaceuticals's Price-to-Tangible-Book
For the Biotechnology subindustry, Dicerna Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dicerna Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Dicerna Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Dicerna Pharmaceuticals's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Dicerna Pharmaceuticals Price-to-Tangible-Book Related Terms
Thank you for viewing the detailed overview of Dicerna Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Dicerna Pharmaceuticals (Dicerna Pharmaceuticals) Business Description
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, cardiovascular diseases, cancers, and other liver problems. The company uses its ribonucleic acid interference technology platform to develop its products. In addition, Dicerna's proprietary GalXC technology focuses on silencing disease-causing genes. The product candidates are nedosiran (for primary hyperoxaluria), belcesiran (for genetic liver disease), DCR-PCSK9 (for cardiovascular disease), and RG6346 (for hepatitis B virus) among others. Dicerna generates revenue by forming collaborative relationships with pharmaceutical companies such as Eli Lilly, Roche, Novo Nordisk, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DRNA has been successfully added to your 